/
Immunology
Myasthenia Gravis
36
Pipeline Programs↗
91
Active Trials↗
39
Companies Involved↗
Myasthenia Gravis is a moderately active landscape with 36 programs across 39 companies. The most active players are Argenx, UCB, AstraZeneca. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical12
Phase 16
Phase 25
Phase 313
Approved
No programs
Analysis
Modality Breakdown
60%
Small molecule
18 of 30 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 89% of 36 pipeline programs.
Analysis
Trial Status
175
clinical trials
Completed57 · 33%
Recruiting51 · 29%
Active, not recruiting19 · 11%
Not yet recruiting18 · 10%
Terminated14 · 8%
Unknown status10 · 6%
Other6 · 3%
Clinical Trials
Trial Activity
175 trials
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)